Cathie Wood is the all-star stock picker in charge of the funds at ARK Invest, and she's a favorite among fans of high-growth stocks. Wood divides her funds into specific market verticals like disruptive innovation, space exploration, next-generation internet, and cryptocurrency.

She's unusual among tech funds in that ARK doesn't shy away from the biotech sector. She has a fund that is focused on the genomics revolution. These three Motley Fool contributors checked out her holdings, and found three investments that they love. Here's why they are bullish on Fate Therapeutics (NASDAQ: FATE), Veracyte (NASDAQ: VCYT) and Adaptive Biotechnologies (NASDAQ: ADPT). 

George Budwell (Fate Therapeutics): Cell therapy has proved to be an important new modality for a host of liquid tumors. But several key problems are still inhibiting the growth of this groundbreaking tech.

Continue reading

Source Fool.com